07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

Scripps Research Institute, Opko deal

Scripps granted Opko worldwide rights to develop and commercialize antibiotics that inhibit lipoprotein signal peptidase (LSPA). The antibiotics were discovered using a high throughput screening technology that Opko in-licensed from Scripps. Opko said it...